The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...

Our data clearly show that it is feasible and safe to implement stepwise acceleration of nivolumab and pembrolizumab administration to a 10-minute infusion time,” the researchers wrote.

Checkpoint Therapeutics, Inc. ("Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a ...

Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy ...

AstraZeneca has vowed to spend over $10 billion on R&D deals in Asia, focusing on China, amid ongoing fraud scandal investigations.

Late-breaking data showed almost all patients achieved normal blood clotting and vessel repair after bentracimab infusion.

Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, toda ...

The most common adverse reactions included systemic infusion-related reactions and hypersensitivity ... to PEMGARDA and national variant frequencies. VYD2311 is a novel monoclonal antibody (mAb) ...